iX Biopharma Ltd (42C) said on Jul, 14 2026 that it has allotted and issued 2.92 million new ordinary shares following the exercise of warrants priced at 0.06 Singapore dollars each.

The issuance comprises 1.00 million shares to Director Albert Ho Shing Tung and 15,301 shares to Centrum Capital Pte Ltd, a company in which Ho is deemed to have an interest.

As a result, the company’s outstanding share capital has risen to 1.08 billion shares from 1.07 billion shares.

To date, 41.27 million warrants, representing 71.76% of the series, have been exercised, leaving 16.24 million warrants outstanding. The remaining warrants will expire at 5:00 p.m. on Jul, 17 2026 if not exercised.